Patents Assigned to JUVENTAS CELL THERAPY LTD.
  • CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF
    Publication number: 20230201261
    Abstract: A chimeric antigen receptor, comprising an amino acid sequence shown in SEQ ID NO. 1. A nucleic acid encoding the chimeric antigen receptor, a vector comprising the nucleic acid, an immune effector cell comprising the chimeric antigen receptor, the nucleic acid molecule and/or the vector, a method for preparing the immune effector cell, a composition comprising the immune effector cell, and use of the chimeric antigen receptor.
    Type: Application
    Filed: November 17, 2022
    Publication date: June 29, 2023
    Applicant: JUVENTAS CELL THERAPY LTD.
    Inventors: Jianxiang WANG, Min WANG, Lulu LV, Lin SHI, Na AN, Rui WANG, Yun LIU
  • PLASMID COMBINATION AND APPLICATION THEREOF IN PREPARING MODIFIED IMMUNE CELLS
    Publication number: 20230146337
    Abstract: Provided in the present disclosure is a method for using a four-plasmid system to prepare modified immune effector cells. The method comprises: forming a lentivirus by using four plasmids within 293T cells, extracting and obtaining the lentivirus, then transfecting immune effector cells by using the lentivirus, and expressing a chimeric antigen receptor. Also provided in the present disclosure is a use of the immune effector cell obtained by using the described method and of a composition containing the immune effector cell.
    Type: Application
    Filed: October 5, 2022
    Publication date: May 11, 2023
    Applicant: JUVENTAS CELL THERAPY LTD.
    Inventors: Yun LIU, Lin SHI, Lulu LV, Pan XIE, Mengmeng CAO, Wang YANG, Jiaxing YANG, Fei WANG, Rui WANG
  • CD19-targeted chimeric antigen receptor and use thereof
    Patent number: 11547728
    Abstract: A chimeric antigen receptor, comprising an amino acid sequence shown in SEQ ID NO. 1. A nucleic acid encoding the chimeric antigen receptor, a vector comprising the nucleic acid, an immune effector cell comprising the chimeric antigen receptor, the nucleic acid molecule and/or the vector, a method for preparing the immune effector cell, a composition comprising the immune effector cell, and use of the chimeric antigen receptor.
    Type: Grant
    Filed: August 26, 2021
    Date of Patent: January 10, 2023
    Assignee: Juventas Cell Therapy Ltd.
    Inventors: Jianxiang Wang, Min Wang, Lulu Lv, Lin Shi, Na An, Rui Wang, Yun Liu
  • Plasmid combination and application thereof in preparing modified immune cells
    Patent number: 11497771
    Abstract: Provided in the present disclosure is a method for using a four-plasmid system to prepare modified immune effector cells. The method comprises: forming a lentivirus by using four plasmids within 293T cells, extracting and obtaining the lentivirus, then transfecting immune effector cells by using the lentivirus, and expressing a chimeric antigen receptor. Also provided in the present disclosure is a use of the immune effector cell obtained by using the described method and of a composition containing the immune effector cell.
    Type: Grant
    Filed: August 26, 2021
    Date of Patent: November 15, 2022
    Assignee: JUVENTAS CELL THERAPY LTD.
    Inventors: Yun Liu, Lin Shi, Lulu Lv, Pan Xie, Mengmeng Cao, Wang Yang, Jiaxing Yang, Fei Wang, Rui Wang
  • PLASMID COMBINATION AND APPLICATION THEREOF IN PREPARING MODIFIED IMMUNE CELLS
    Publication number: 20220040233
    Abstract: Provided in the present disclosure is a method for using a four-plasmid system to prepare modified immune effector cells. The method comprises: forming a lentivirus by using four plasmids within 293T cells, extracting and obtaining the lentivirus, then transfecting immune effector cells by using the lentivirus, and expressing a chimeric antigen receptor. Also provided in the present disclosure is a use of the immune effector cell obtained by using the described method and of a composition containing the immune effector cell.
    Type: Application
    Filed: August 26, 2021
    Publication date: February 10, 2022
    Applicant: JUVENTAS CELL THERAPY LTD.
    Inventors: Yun LIU, Lin SHI, Lulu LV, Pan XIE, Mengmeng CAO, Wang YANG, Jiaxing YANG, Fei WANG, Rui WANG
  • CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF
    Publication number: 20220040234
    Abstract: A chimeric antigen receptor, comprising an amino acid sequence shown in SEQ ID NO. 1. A nucleic acid encoding the chimeric antigen receptor, a vector comprising the nucleic acid, an immune effector cell comprising the chimeric antigen receptor, the nucleic acid molecule and/or the vector, a method for preparing the immune effector cell, a composition comprising the immune effector cell, and use of the chimeric antigen receptor.
    Type: Application
    Filed: August 26, 2021
    Publication date: February 10, 2022
    Applicant: JUVENTAS CELL THERAPY LTD.
    Inventors: Jianxiang WANG, Min WANG, Lulu LV, Lin SHI, Na AN, Rui WANG, Yun LIU